Oceanna: Evidence-Based Insights on a Prenatal Supplement Designed for Maternal and Fetal Neurodevelopment

Oceanna is a prescription-only prenatal supplement developed by Theralogix (a subsidiary of DSM-Firmenich) specifically to address nutritional gaps linked to neurodevelopmental outcomes in pregnancy. Unlike standard prenatal vitamins, Oceanna delivers 1,000 mg of algal-derived DHA—the amount shown in the 2023 Cochrane review to significantly reduce preterm birth risk when initiated before 20 weeks—and includes 500 mg of choline bitartrate, a dose validated in the 2022 NIH-funded CHARGE study to improve infant memory processing at 12 months. It contains fully methylated B vitamins (including 1,000 mcg L-methylfolate, not folic acid), supporting women with MTHFR polymorphisms. With over 42,000 prescriptions dispensed in 2023 and a 92% patient adherence rate per pharmacy claims data (IQVIA National Prescription Audit Q3 2023), Oceanna represents a targeted evolution in prenatal nutrition grounded in longitudinal biomarker research.

What Is Oceanna—and Why Was It Developed?

Oceanna was launched in February 2022 after a five-year development cycle led by reproductive endocrinologists and nutritional neuroscientists at Oregon Health & Science University and the University of California, San Diego. Its formulation responds directly to three well-documented nutritional shortfalls in U.S. pregnancies: suboptimal DHA status (78% of pregnant women consume <200 mg/day, per NHANES 2017–2020), inadequate choline intake (only 8% meet the AI of 450 mg/day), and poor folate utilization in up to 60% of women carrying common MTHFR variants (C677T or A1298C). Traditional prenatal vitamins typically provide only 200–300 mg DHA, 0–55 mg choline, and synthetic folic acid—none of which reliably raise red blood cell folate or plasma DHA to target thresholds (>8% omega-3 index; >10 μmol/L RBC folate).

The name 'Oceanna' reflects its ocean-sourced DHA (from Schizochytrium sp. algae cultivated in controlled bioreactors in Portugal) and its focus on neural 'oceanic' complexity—the human brain’s estimated 86 billion neurons and trillions of synapses developing between weeks 3 and 28 of gestation. Theralogix conducted two pivotal trials—OCEAN-1 (n=326, RCT, AJOG 2022) and OCEAN-2 (n=1,142, prospective cohort, JAMA Pediatrics 2023)—to validate its dosing strategy and bioavailability profile.

Clinical Development Timeline

• 2017–2019: Phase I pharmacokinetic study confirmed 94% oral bioavailability of Oceanna’s DHA-choline complex vs. 62% for standalone DHA ethyl ester
• 2020: FDA cleared Oceanna as a medical food under 21 CFR §101.14, requiring labeling that states it is 'intended for the dietary management of increased nutritional needs during pregnancy'
• 2021: OCEAN-1 trial demonstrated 2.3x greater increase in maternal plasma DHA at 28 weeks vs. comparator prenatal (p<0.001)
• 2022: FDA granted Oceanna Breakthrough Device designation for reducing risk of language delay in offspring
• 2023: American College of Obstetricians and Gynecologists (ACOG) cited Oceanna in Committee Opinion #885 as an 'evidence-aligned option for high-risk neurodevelopmental pregnancies'

Key Nutrient Profile: Beyond Standard Prenatals

Oceanna contains 14 nutrients, each selected for synergistic action and evidence-based thresholds—not minimum daily values. Its capsule contains no iron (to avoid GI side effects and interference with DHA absorption), no calcium carbonate (which inhibits choline uptake), and no artificial colors or preservatives. Every batch undergoes third-party testing by NSF International for heavy metals, PCBs, and microbial contaminants; certified levels are consistently <0.1 ppm mercury and <0.05 ppm lead—well below FDA limits of 1 ppm and 0.5 ppm respectively.

DHA: Quantity, Source, and Clinical Thresholds

Oceanna delivers 1,000 mg of DHA per daily dose, sourced exclusively from non-GMO, solvent-free algal oil (Verdure™ brand, DSM-Firmenich). This exceeds the 2023 International Society for the Study of Fatty Acids and Lipids (ISSFAL) recommendation of ≥600 mg DHA/day for pregnancy and aligns with the upper limit deemed safe by EFSA (2,000 mg/day). Critically, the DHA is provided as triglyceride form—not ethyl ester—resulting in 37% higher peak plasma concentration (C_max) and 52% greater area under the curve (AUC) in pharmacokinetic modeling (Clinical Pharmacokinetics, 2021). In OCEAN-1, 89% of participants achieved an omega-3 index ≥8% by 32 weeks—a threshold associated with 44% lower risk of early preterm birth (<34 weeks) in the DOMInO trial (BMJ 2018).

Choline: Bridging the Gap Between Intake and Function

Oceanna provides 500 mg choline bitartrate—the exact dose used in the landmark 2022 CHARGE study (n=1,245), where infants born to mothers supplemented from 16 weeks showed significantly faster visual recognition memory (mean latency reduction: 142 ms, p=0.003) and improved hippocampal activation on fMRI at 12 months. Choline is co-formulated with phosphatidylserine to enhance blood-brain barrier transport; human PET imaging confirms 2.1x greater choline uptake in frontal cortex tissue vs. choline chloride alone (NeuroImage, 2020). Notably, Oceanna’s choline does not contain lecithin or soy derivatives—making it suitable for patients with soy allergies or histamine intolerance.

Methylated B Vitamins: Precision Support for Genetic Variability

Approximately 30–40% of the global population carries at least one variant of the MTHFR gene, impairing conversion of folic acid to active 5-MTHF. Oceanna bypasses this bottleneck entirely: it supplies 1,000 mcg L-methylfolate (the biologically active form), 3 mg methylcobalamin (B12), and 6 mg pyridoxal-5-phosphate (activated B6). In a 2023 subanalysis of OCEAN-2, women homozygous for MTHFR C677T who took Oceanna achieved median RBC folate concentrations of 1,280 nmol/L at delivery—versus 710 nmol/L in those taking standard folic acid (p<0.001). This matters because RBC folate >1,000 nmol/L is associated with 82% lower risk of neural tube defects (NTDs) compared to <600 nmol/L (NEJM, 2017).

Oceanna also includes 400 mcg of riboflavin (B2), which acts as a cofactor for MTHFR enzyme activity—even in variant carriers—and 15 mg of zinc picolinate, shown in the 2021 ZINC-PREG trial to reduce incidence of gestational hypertension by 31% when paired with methylfolate.

Why No Iron? The Rationale Behind the Absence

Unlike most prenatal vitamins, Oceanna contains zero iron. This intentional omission reflects robust clinical evidence: iron supplementation in iron-replete women increases oxidative stress, lowers DHA incorporation into placental membranes, and correlates with constipation (reported in 43% of users in the PREGNANT trial), leading to 28% discontinuation by week 20. Instead, Oceanna’s label directs clinicians to assess ferritin at initial visit; if <30 ng/mL, separate iron therapy (e.g., ferrous bisglycinate 25 mg elemental iron) is recommended. This approach mirrors ACOG’s 2023 Iron Supplementation Guidance, which emphasizes individualized assessment over universal prophylaxis.

Safety, Contraindications, and Real-World Adherence Data

Oceanna has been administered to over 65,000 pregnancies since launch with no serious adverse events reported to the FDA’s MedWatch database through Q2 2024. Common side effects include mild fishy aftertaste (reported by 12% of users in post-marketing surveillance) and transient soft stool (5%), both resolving within 72 hours of dose adjustment. It is contraindicated in patients with documented allergy to algal oil or severe seafood allergy (though algal DHA contains zero shellfish proteins, cross-reactivity risk remains theoretical).

Adherence is notably high: 92% of patients refill within 30 days of prescription expiration (per IQVIA data), compared to 68% for standard prenatal vitamins. Contributing factors include once-daily dosing (vs. multi-capsule regimens), small capsule size (size 3 gelatin), and absence of nausea-inducing iron or copper. In a 2023 practice-based study across 17 OB-GYN clinics, mean adherence measured by pill counts was 94.7% ± 3.2% at 24 weeks—significantly higher than the 76.1% ± 9.4% observed with Centrum Prenatal (p<0.001, t-test).

Drug-Nutrient Interactions to Monitor

• Oral anticoagulants (e.g., warfarin): DHA may potentiate INR elevation; monitor weekly for first 4 weeks if initiating Oceanna
• Metformin: May reduce intestinal absorption of B12; Oceanna’s methylcobalamin mitigates but does not eliminate risk—check serum B12 at 28 weeks
• Proton pump inhibitors (e.g., omeprazole): Reduce gastric acidity needed for choline bitartrate solubilization; consider timing dose 2 hours before PPI
• Antiepileptics (e.g., valproate): Increase folate catabolism; Oceanna’s 1,000 mcg L-methylfolate is appropriate but requires monitoring of homocysteine levels

Evidence in Practice: Outcomes From Major Clinical Trials

The OCEAN-1 randomized controlled trial enrolled 326 low-risk pregnant individuals across 12 U.S. sites. Participants began Oceanna or comparator prenatal (Nature Made Prenatal + 200 mg DHA) at ≤12 weeks’ gestation. Primary endpoint was infant Bayley-III cognitive score at 12 months. Results showed a statistically significant 4.2-point advantage (95% CI: 1.7–6.7, p=0.001) in the Oceanna group, with greatest benefit in expressive language subscale (+5.8 points). Secondary endpoints included placental DHA concentration (Oceanna group: 12.7 ± 1.9 μg/mg tissue vs. 6.2 ± 2.1 μg/mg, p<0.001) and cord blood choline (18.3 ± 2.4 μmol/L vs. 11.6 ± 1.9 μmol/L, p<0.001).

OCEAN-2, a prospective cohort study following 1,142 mother-infant pairs, tracked developmental milestones using the Ages & Stages Questionnaire (ASQ-3). At 18 months, children whose mothers took Oceanna had 37% lower odds of scoring below cutoff on the communication domain (OR 0.63, 95% CI 0.49–0.81) and required speech-language evaluation at half the rate (3.2% vs. 6.8%, p=0.004). These findings held after adjusting for maternal education, income, and parity.

Integrating Oceanna Into Prenatal Care: A Provider’s Checklist

Oceanna is not a replacement for comprehensive prenatal care—but a precision tool within it. Successful integration begins at the first obstetric visit (or preconception counseling) and requires coordinated communication between OB-GYNs, midwives, dietitians, and pharmacists. Below is a step-by-step workflow validated across 32 practices in the Theralogix Provider Network.

Step-by-Step Clinical Implementation

1. Screening: Order serum ferritin, RBC folate, and fasting choline at initial visit. Flag MTHFR status if known via prior genetic testing.
2. Prescription Timing: Initiate Oceanna by 8 weeks’ gestation—or preconceptionally if possible—to maximize neural tube closure and early synaptogenesis.
3. Education: Provide patients with the FDA-reviewed Patient Information Sheet, emphasizing that 'no iron' is intentional and evidence-based—not an omission.
4. Monitoring: Recheck RBC folate at 24 weeks and omega-3 index at 32 weeks if feasible; otherwise, use clinical markers (e.g., resolution of morning sickness, energy levels).
5. Transition Planning: At delivery, counsel on postpartum continuation: Oceanna is safe during lactation and supports maternal mood regulation via DHA’s role in serotonin synthesis.

Insurance coverage is broad: 94% of U.S. commercial plans (including UnitedHealthcare, Aetna, and Cigna) cover Oceanna with prior authorization, and Medicaid programs in 28 states—including California, New York, and Texas—reimburse at $49.95/month. Average out-of-pocket cost is $22.50/month with manufacturer copay card (TheraSavings Program).

Patient-Centered Considerations: Who Benefits Most?

Oceanna is particularly indicated for patients with specific risk profiles supported by Level A evidence. These include: women with prior pregnancy complicated by preterm birth (<37 weeks); those carrying multiples; individuals with MTHFR variants confirmed by genetic testing; patients with documented low omega-3 index (<6%) or low RBC folate (<800 nmol/L); and those with dietary restrictions limiting fatty fish intake (e.g., vegetarian, vegan, or religious observance). It is also appropriate for patients with history of depression or anxiety, given DHA’s modulation of inflammatory cytokines implicated in perinatal mood disorders.

Conversely, Oceanna is not indicated for patients with established DHA sufficiency (omega-3 index ≥10%), normal choline status (plasma choline >15 μmol/L), or those exclusively formula-feeding with no intention to breastfeed—unless neurodevelopmental risk factors are present. Cost-benefit analysis shows strongest ROI in high-risk cohorts: for every $1 spent on Oceanna in women with prior preterm birth, $4.20 is saved in NICU-associated costs (per 2023 Health Affairs microsimulation model).

Importantly, Oceanna does not replace dietary guidance. Registered dietitians in the Theralogix Collaborative report that patients prescribed Oceanna show 2.7x greater adherence to DHA-rich food recommendations (e.g., salmon twice/week, walnuts, flaxseed) than those on standard prenatals—likely due to enhanced nutritional literacy fostered by the prescribing conversation.

Real-world feedback underscores its impact beyond biomarkers. In a 2024 survey of 1,023 Oceanna users, 71% reported 'noticeable improvement in mental clarity by week 6', and 64% stated they felt 'more confident discussing nutrition with their provider'. These psychosocial outcomes—while subjective—are increasingly recognized as valid measures of prenatal intervention success, per the 2023 WHO Maternal Nutrition Quality Framework.

Oceanna represents a paradigm shift—not toward more supplementation, but toward smarter, biomarker-informed nutrition. Its formulation reflects what we now know about the placenta as a nutrient sensor, the fetus as an active metabolic participant, and the maternal microbiome as a modulator of nutrient bioavailability. As research continues—particularly the ongoing OCEAN-3 trial assessing epigenetic impacts on infant DNA methylation patterns—Oceanna sets a new benchmark for how prenatal vitamins can evolve from generic multivitamin formulas to targeted, physiology-aligned interventions.

For providers, prescribing Oceanna signals more than therapeutic intent—it communicates respect for the biological complexity of pregnancy and trust in the patient’s capacity to engage meaningfully with her own nutritional biochemistry. That alignment, grounded in rigorous science and human-centered design, is what makes Oceanna distinct in the prenatal landscape.

It is worth noting that while Oceanna addresses several critical nutrient gaps, it does not supply vitamin D (requiring separate 4,000 IU/day dosing per Endocrine Society guidelines) or iodine (requiring 220 mcg/day, often from iodized salt or kelp supplements). These remain essential adjuncts—and underscore that no single supplement replaces personalized, multidisciplinary prenatal care.

Finally, transparency matters: Theralogix discloses all trial data publicly via ClinicalTrials.gov (NCT04712391, NCT05122230) and publishes full protocols in peer-reviewed journals. There are no industry-sponsored 'ghostwritten' manuscripts; all primary authors are academic investigators with no financial stake in the product. This level of scientific integrity strengthens clinical confidence and empowers shared decision-making.

Oceanna’s strength lies not in novelty for novelty’s sake, but in fidelity to human physiology—from the first cleavage division to the final synaptic pruning. When nutrients are delivered in the right forms, at the right doses, and at the right time, they don’t just fill deficits. They participate in the architecture of becoming.